| Biomarker ID | 114 |
| PMID | 17977648 |
| Year | 2008 |
| Biomarker | PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2. |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Upregulated (Log2 fold change: 2-7.9 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(PCDH7):-Platelet degranulation Homo sapiens R-HSA-114608,Response to elevated platelet cytosolic Ca2+ Homo sapiens R-HSA-76005,Platelet activation, signaling and aggregation Homo sapiens R-HSA-76002,Hemostasis Homo sapiens R-HSA-109582 |
| Experiment | Androgen Independent PCa Vs Androgen Dependent PCa |
| Type of Biomarker | Prognostic |
| Cohort | Human prostate cancer cell lines (LNCaP-C33, LNCaP-C81, LNCaP-C4-2, PC3 and DU145) were utilized in the study. LNCaP-C33 (androgen-sensitive) and LNCaP-C81 (androgen-independent) cell lines were selected. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Only PP2A gene was validated on human patient cohort |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on human patient cohort |
| Technical Name | PCDH7, NRXN3, TPTE, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS1, HGF, CALN1, ADAM-TS3, NPLOC4, MYO3A, GNA11, PAGE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, ANTXR1, XAGE1A, GAS2 |